Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CRABP2 encodes a member of the retinoic acid (RA, a form of vitamin A) binding protein family and lipocalin/cytosolic fatty-acid binding protein family. Additionally we are shipping CRABP2 Antibodies (172) and CRABP2 Proteins (16) and many more products for this protein.
Showing 6 out of 19 products:
Zebrafish Crabp2a and Crabp2b are essential for expression of hoxb4 and hoxb5 in the hindbrain.
Chromosome mapping of CRABP1 (show RBP1 ELISA Kits) AND CRABP2 in swine.
Semiquantitative and quantitative analyses of the markers RARA (show RARA ELISA Kits) and CRABP2 indicate their potential as biomarkers for tumor progression and their participation in nephroblastoma tumorigenesis
These data suggest a retinoic acid-independent, non-tumor suppressor role of CRABP2 for the survival of Malignant peripheral nerve sheath tumor (MPNST) cells in vitro. Targeting CRABP2 overexpression may represent a unique approach for the treatment of human MPNST.
A high expression ratio between FABP5 (show FABP5 ELISA Kits) and CRABPII may be related to CP tumor recurrence and ATRA could be a potential therapeutic agent for CP chemotherapy.
Holo-CRABPs had higher affinity for CYP26B1 than free atRA, but both apo-CRABPs(CRABP-I and CRABP-II ) inhibited the formation of 4-OH-RA by CYP26B1.
reducing CRABP2 levels may enhance the therapeutic index of Retinoic acid in glioblastoma multiforme patients
The anticarcinogenic activities of CRABP2 are mediated by both HuR and RAR.
CBX3 (show CBX3 ELISA Kits) and CRABP2 expression was markedly increased in lung cancer tissues
we demonstrated significant changes in CRABP1 and CRABP2 expression in non-small cell lung cancer samples
Reengineering of cellular retinoic acid binding protein II (CRABPII) to be capable of binding retinal as a protonated Schiff base is described
CRABP2 controls mRNA stabilization by HuR (show ELAVL1 ELISA Kits).
Results show that acetylation status of CRABPII directly influences embryonic stem cell differentiation in response to retinoic acid.
all three proteins (RDH10, RALDH2 (show ALDH1A2 ELISA Kits), and CRABP2) appeared to be required for ATRA production induced by activation of PPARgamma (show PPARG ELISA Kits)
CRABP2 promotes myoblast differentiation and is modulated by the transcription factors MyoD (show MYOD1 ELISA Kits) and Sp1 (show SP1 ELISA Kits) in C2C12 cells.
observations emphasize the important role of CRABP-II in regulating the transcriptional activity of RA through RAR, and they demonstrate that repression of this gene is critical for allowing adipogenesis to proceed
Localization revealed epithelial-mesenchymal interactions, differentiation differences within the retinoic acid biosynthesis and signaling pathway, and observations on nuclear versus cytoplasmic locations of Crabp2 and RA receptors (alpha, beta, gamma).
Increases in CRABPI and II transcripts in the absence of leukemia inhibitory factor (show LIF ELISA Kits) may regulate aspects of embryonic stem cell differentiation in response to retinol.
TIS7 inhibits CRABP II expression during axonal regeneration, thereby modulating retinoic acid signalling. Hence, neurite initiation and branching are regulated by a negative feedback mechanism involving TIS7 and CRABP II.
This gene encodes a member of the retinoic acid (RA, a form of vitamin A) binding protein family and lipocalin/cytosolic fatty-acid binding protein family. The protein is a cytosol-to-nuclear shuttling protein, which facilitates RA binding to its cognate receptor complex and transfer to the nucleus. It is involved in the retinoid signaling pathway, and is associated with increased circulating low-density lipoprotein cholesterol. Alternatively spliced transcript variants encoding the same protein have been found for this gene.
cellular retinoic acid-binding protein 2
, cellular retinoic acid binding protein 2
, cellular retinoic acid-binding protein II
, cellular lipid-binding protein
, cellular retinoic acid binding protein II